Her name is Laura.
With hot flashes.
She is a fit, conscious, sporty, sexually active lady. In addition to paying particular attention to our environment, she likes cycling. Her main problem is vaginal dryness. She does not want to take oral medicine because she is afraid of liver issues, however she wants to stay active in all areas.
What
Estradiol 1,53 mg/spray transdermal spray (equivalent to 1.58 mg of estradiol hemihydrate).
Therapy for
Oestrogen deficiency symptoms in post-menopausal women. The experience in treating women older than 65 years is limited.
Dominant symptoms
Hot flashes, sleeping problem, mood changes.1
Product benefit
'Spray and go'. Transdermal HRT in a simple spray, minimal systemic absorption.
Easy to use, invisible, quick drying spray, Lenzetto is designed for convenience, fits around her lifestyle. Precise dosing means that with Lenzetto, she can be confident in applying the right dose.
Important to know
Lenzetto successfully combines the advantages of non-occlusive and occlusive transdermal systems. Not metabolized by the liver and can deliver drugs with poor oral bioavailability (does not interact with other drugs in the liver compared to oral tablets).2,3
Keep your patients safe1
For women with a uterus, a progestogen that is neutral on coagulation parameters is recommended.
References
1. Baber, 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy, 2016.
2. Algin-Yapar E et al. J. Pharm Res 2014;13:469;
3. Kopper NW et al. Drug Des Devel Ther. 2009;2:193-202.
Her name is Valerie.
With vaginal atrophy.
She is a fit, conscious, sporty, sexually active lady. In addition to paying particular attention to our environment, she likes cycling. Her main problem is vaginal dryness. She does not want to take oral medicine because she is afraid of liver issues, however she wants to stay active in all areas.
What
Estradiol hemihydrate 10 microgram vaginal tablets with only 1 applicator in the package, reduced waste.
Therapy for
Vaginal atrophy due to estrogen deficiency in post-menopausal women. The experience in treating women older than 65 years is limited.
Dominant symptoms
Vaginal dryness, burning, urgent or frequent urination and even incontinence, as well as dyspareunia, severe enough in some to prevent penetrative sexual intercourse.1-3
Product benefit
Local effect: (comfort where she needs it, it acts where it's needed), minimal systemic absorption. -
Environmentally sustainable: reduced plastic waste with a single multi-use CE-certified and recyclable applicator, disposed via household waste; supporting the NHS Long-Term Plan to reduce the volume of single use plastics by having only 1 reusable applicator in each package.4
Important to know
Simple dosing.
When vaginal atrophy is the only symptom, local estrogen treatment should be the first choice, as it minimizes the degree of systemic estrogen absorption.5
References
1. Palacios S et al. Climacteric 2018;21:286-91
2. Faubion SS et al. Mayo Clin Proc. 2017;92:1842-49.
3. Reiter S. Int J Gen Med 2013;6:153–58
4. NHS Long-Term Plan. Available at: (Last accessed: October 2021).
5 Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004;7:103-11.
Her name is Klaire.
With general menopause symptoms.
She is afraid of a bone fracture and mainly weight gaining due to hormone replacement. (Fear of obesity and edema). She prefers classic menopause medication: a proven, well-known solution.
What
Estradiol/drospirenone film-coated oral tablet (1 mg estradiol (as 1.03 mg estradiol hemihydrate) and 2 mg drospirenone; continuous once-daily dosing).
Therapy for
Climacteric syndrome and prevention of osteoporosis in post-menopausal women. The experience in treating women older than 65 years is limited.
Dominant symptoms Climacteric syndrome, osteoporosis.
Product benefit
Weight control, complex effect, bone protection. Balanced hormone replacement.1,2
Important to know
The synthetic progestogen drospirenone provides the pregestational component of the HRT and has a unique pharmacology that differentiates our product from other combined oral HRTs. E2-DRSP has a positive effect on bone mineral density and a potentially beneficial effect on lipids.3
Keep your patients safe1
HRT is associated with the chance of developing venous thromboembolism (VTE, deep vein thrombosis or pulmonary embolism). Pay particular attention in case of major surgery, obesity (BMI > 30 kg/m2), systemic lupus erythematous (SLE) and cancer.
References
1. Palacios S, Foidart JM, Genazzani AR. Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 2006;55:297-307
2. Foidart JM. Added benefits of drospirenone for compliance. Climacteric 2005;8 Suppl 3:28-34.
3. Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004;7:103-11.